KSrelief chief meets with CEPI CEO in Riyadh to discuss epidemic, pandemic preparedness

KSrelief chief Dr. Abdullah bin Abdulaziz Al-Rabeeah met with CEO of Coalition for Epidemic Preparedness Innovations (CEPI) Dr. Richard Hatchett in Riyadh. (SPA)
1 / 2
KSrelief chief Dr. Abdullah bin Abdulaziz Al-Rabeeah met with CEO of Coalition for Epidemic Preparedness Innovations (CEPI) Dr. Richard Hatchett in Riyadh. (SPA)
KSrelief chief Dr. Abdullah bin Abdulaziz Al-Rabeeah met with CEO of Coalition for Epidemic Preparedness Innovations (CEPI) Dr. Richard Hatchett in Riyadh. (SPA)
2 / 2
KSrelief chief Dr. Abdullah bin Abdulaziz Al-Rabeeah met with CEO of Coalition for Epidemic Preparedness Innovations (CEPI) Dr. Richard Hatchett in Riyadh. (SPA)
Short Url
Updated 17 May 2022
Follow

KSrelief chief meets with CEPI CEO in Riyadh to discuss epidemic, pandemic preparedness

KSrelief chief meets with CEPI CEO in Riyadh to discuss epidemic, pandemic preparedness
  • Dr. Hatchett praised the support offered by the Kingdom of Saudi Arabia, represented by KSrelief, to help CEPI develop COVID-19 vaccines

RIYADH: King Salman Humanitarian Aid and Relief Center (KSrelief) chief Dr. Abdullah bin Abdulaziz Al-Rabeeah met with CEO of Coalition for Epidemic Preparedness Innovations (CEPI) Dr. Richard Hatchett in Riyadh on Tuesday.

During the meeting, both sides discussed means to enhance cooperation related to providing suitable vaccines to combat the novel coronavirus (COVID-19) pandemic along with other contagious diseases.

They also discussed the need to support needy countries with weaker health sectors, study mechanisms to support CEPI to transfer the technology of manufacturing vaccines, as well as benefiting from Saudi Arabia's logistic and humanitarian role in this regard.

Dr. Hatchett praised the support offered by the Kingdom of Saudi Arabia, represented by KSrelief, to help CEPI develop COVID-19 vaccines and offer them to the needy, referring to the solid strategic relations between the two sides.

CEPI is a foundation that takes donations from public, private, philanthropic, and civil society organisations, to finance independent research projects to develop vaccines against emerging infectious diseases.